Dr. Le Van Be, Director of the National Institute of Vaccines and Biologicals, said: "The influenza A / H5N1 vaccination for stage 2 and 3 stage testers is successful.
Production of vaccines in Vietnam.
High doses of this vaccine have been shown to be immunogenic, according to standard test methods. This clinical trial was conducted by Ho Chi Minh City Pasteur Institute in Ben Luc District, Long An Province.
This study evaluated the safety and immunogenicity of different doses in healthy adults.
A total of 75 healthy men and women aged 18 to 30 years participated in phase 1, double blind, randomized, placebo-controlled clinical trial.
Each subject received two IVACFLU-H5N1 injections: high dose or low dose, or placebo-controlled phosphate buffer (PBS). 32 volunteers received high doses of IVACFLU-H5N1 at 15mcg / 0.5ml and 31 volunteers received low doses at 7.5mcg / 0.5ml. Twelve volunteers received a placebo. The results showed that the vaccine was well tolerated and immunized.
At the ceremony, Dr. Le Van Be, Director of IVAC confirmed: "IVACFLU-A / H5N1 vaccine is ready to test phase 2 and 3".
He also looks forward to continuing his partnership with his colleagues to reach the recruitment of licensed and industrial-scale vaccines that meet the needs of local and regional use. global in the event of a pandemic.
According to TS Baby, seasonal flu causes 250,000 to 500,000 deaths and up to 5 million severe cases each year. If a highly pathogenic strain is present, the flu can cause millions of deaths worldwide. Vietnam has recorded more than one million cases of influenza-like illness each year and has also had cases of human infection with avian influenza A / H5N1 - cases with high mortality. This flu strain is being monitored to see if it can be transformed into a new viral strain that is spread in humans and could pandemic in the future.
The efforts of IVAC in research and testing to produce influenza A / H5N1 vaccines in Vietnam are not only beneficial to the Vietnamese people (who do not have a stable source of flu vaccine produced domestically) ) but also to provide vaccines in the region and in the world in the event of a pandemic.
According to WHO, the world's resources for producing and developing influenza vaccines are almost limited to only a few manufacturers, the current global vaccine production has fallen short of demand and makes the vaccine more affordable. low-income and middle-income countries do not have access to life-saving tools. More involvement of vaccine manufacturers such as IVAC is very important when there is a pandemic.